Latest News From Lumira Ventures

Satsuma Pharmaceuticals Completes $90.8M Initial Public Offering

Jennifer Schram Main Page, Portfolio News, Press Release, Satsuma Pharmaceuticals

SOUTH SAN FRANCISCO, Calif. — Satsuma Pharmaceuticals, Inc. (“Satsuma” or the “Company”) (Nasdaq: STSA), a clinical-stage biopharmaceutical company developing STS101 (dihydroergotamine (DHE) nasal powder) for the acute treatment of migraine, today announced the closing of the Company’s previously announced initial public offering …

Satsuma Pharmaceuticals Inc. Proposes Initial Public Offering of Common Stock

Jennifer Schram Portfolio News, Press Release, Satsuma Pharmaceuticals

SOUTH SAN FRANCISCO, Calif., Sept. 3, 2019 /PRNewswire/ — Satsuma Pharmaceuticals, Inc. (“Satsuma”), a clinical-stage biopharmaceutical company developing STS101 (dihydroergotamine (DHE) nasal powder) for the acute treatment of migraine, today announced that it has commenced an underwritten initial public offering of …

Satsuma Pharmaceuticals Appoints Elisabeth Sandoval to Board of Directors

Jennifer Schram Portfolio News, Press Release, Satsuma Pharmaceuticals

Commercial leader brings recent migraine space experience to Satsuma as it advances lead product candidate STS101 into Phase 3 development SOUTH SAN FRANCISCO, Calif., May 29, 2019 /PRNewswire/ — Satsuma Pharmaceuticals, Inc. (“Satsuma” or “the Company”), a Phase 3-stage biopharmaceutical company developing STS101, …

Satsuma Pharmaceuticals Raises $62 Million in Series B Preferred Stock Financing

Jennifer Schram Portfolio News, Press Release, Satsuma Pharmaceuticals

Funding supports Phase 3 development of STS101 for the acute treatment of migraine, including pivotal Phase 3 efficacy trial with planned initiation in Q3 2019 SOUTH SAN FRANCISCO, Calif., April 24, 2019 /PRNewswire/ — Satsuma Pharmaceuticals, Inc. (“Satsuma” or “the Company”), a clinical-stage biopharmaceutical …